You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四环医药(00460.HK)附属获授予琥珀酸美托洛尔缓释片在内地推广权
阿思达克 05-28 12:06
四环医药(00460.HK)公布,附属公司海南四环医药司与佛山德芮可制药签订了有关琥珀酸美托洛尔缓释片23.75mg/47.5mg/95mg/190mg产品总营销服务协议。

根据该协议,德芮可向集团授予该产品於中国大陆地区之产品独家市场推广权。推广权期限为该产品任一剂量取得中国国家药品监督管理局(NMPA)药物注册批件和╱或上市许可之日起满5年。集团於该协议期满後拥有同等条件下的优先续约权。

根据中国米内资料库统计,琥珀酸美托洛尔缓释片於2018年中国城市公立医院之销售额约为13亿元人民币。目前市场上除了阿斯利康的原研产品独家在售外,尚无仿制药获批。此次集团所代理的该产品目前处於优先评审阶段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account